ZielBio finalized a $15 million funding round this summer to complete initial trials of a cancer treatment drug it hopes to bring to market in 2024.
The findings may open the door for early testing for coronary artery disease risk in patients with lupus, the researchers wrote.
Acumen’s ACU193, an Anti-Amyloid Beta Oligomer Antibody, Granted FDA Fast Track Designation for Alzheimer's Disease
ACU193 is currently being studied in the Phase 1 INTERCEPT-AD trial designed to assess safety and proof of mechanism of ACU193.
BIO-CAT Microbials continues to scale up their probiotic pipeline with their latest microbial strain, Bacillus subtilis BS50.
Bonumose says FDA Sides With High Fructose Corn Syrup Producers and Against Consumers, By Suppressing Truthful Information About Tagatose
Internal FDA documents discovered via the Freedom of Information Act indicate a potential FDA bias against health-focused innovation and in favor of industrial corn sweetener producers.
Late next year, dermatologists will be able to submit a biopsy for genetic analysis and Ampel will then identify the best drugs for treatment.
Adial Pharmaceuticals Announces Research Collaboration with UC San Diego to Advance Purnovate’s Adenosine Compounds as Potential Treatments for Inflammatory Diseases & Disorders
The research collaboration agreement will further evaluate the Company’s proprietary adenosine analogs as a potential treatment for inflammatory diseases.
Virginia Based AMPEL BioSolutions' Machine Learning Breakthrough Predicts Drug Options for Inflammatory Skin Diseases
AMPEL BioSolutions today announces a breakthrough in precision and personalized medicine that could revolutionize the way doctors treat inflammatory skin diseases.
FDA Clears Caretaker Medical’s Wireless Monitor for NonInvasive & Continuous Cardiac Output, Stroke Volume, and Advanced Hemodynamics
This is the company’s 5th FDA Clearance expanding the capabilities of its industry leading VitalStream™ wireless wearable.